ALLO - Allogene Therapeutics, Inc. Latest News | Finranks

ALLO - Allogene Therapeutics, Inc. Latest News | Finranks

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4

ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2025.

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus

ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.

Videos

No Data

There is no data to display